Zoetis Inc. (NYSE:ZTS) Shares Sold by NBT Bank N A NY

NBT Bank N A NY trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 25.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,272 shares of the company’s stock after selling 1,437 shares during the period. NBT Bank N A NY’s holdings in Zoetis were worth $696,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Callahan Advisors LLC increased its holdings in shares of Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares during the period. Pensionfund Sabic grew its holdings in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after acquiring an additional 4,000 shares during the period. CIBC Asset Management Inc grew its holdings in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after acquiring an additional 46,050 shares during the period. PFW Advisors LLC acquired a new position in Zoetis during the fourth quarter worth about $1,764,000. Finally, Alberta Investment Management Corp grew its holdings in Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after acquiring an additional 28,700 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

Zoetis Trading Up 0.8 %

NYSE:ZTS opened at $171.70 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33. The stock’s 50-day moving average is $166.91 and its two-hundred day moving average is $176.66. The stock has a market cap of $76.89 billion, a PE ratio of 31.39, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s payout ratio is 36.56%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.